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A Major Role for TPPII in Trimming
Proteasomal Degradation Products
for MHC Class I Antigen Presentation
subsequently degraded (Koopmann et al., 2000; Roelse
et al., 1994). MHC class I molecules usually bind pep-
tides of nine amino acids with appropriate anchor resi-
dues (Rammensee et al., 1993). The TAP transporter
also prefers to translocate peptides of around nine
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amino acids (Momburg et al., 1994a), although substratePlesmanlaan 121
peptides up to 40 amino acids can be translocated into1066 CX Amsterdam
the ER lumen as well (Koopmann et al., 1996). TAP showsThe Netherlands
minor specificity for peptide sequences (Momburg et al.,2 Department of Immunohematology
1994b), which is not unexpected since it has to provideand Blood Transfusion
different class I molecules with peptide epitopes.Leiden University Medical Center
In vitro experiments suggest that most peptides gen-2300 RC Leiden
erated by the proteasome will probably have an incor-The Netherlands
rect size for direct class I loading (Kisselev et al., 1999;
Toes et al., 2001). N-terminal extended epitopes can be
trimmed to the correct size for MHC class I binding bySummary
cytoplasmic and ER luminal aminopeptidases, but most
peptides will be completely recycled into free aminoIntracellular proteins are degraded by the proteasome,
acids (Reits et al., 2003). Several cytoplasmic amino-and resulting peptides surviving cytoplasmic peptidase
and endopeptidases have been identified, including leu-activity can be presented by MHC class I molecules.
cine aminopeptidase (LAP) (Beninga et al., 1998), tripep-Here, we show that intracellular aminopeptidases de-
tidyl peptidase II (TPPII) (Geier et al., 1999; Tomkinson,grade peptides within seconds, almost irrespectively
1999), thimet oligopeptidase (TOP) (Mo et al., 1999),of amino acid sequence. N- but not C-terminal exten-
bleomycin hydrolase (BH) (Bromme et al., 1996; Stoltzesion increases the half-life of peptides until they are
et al., 2000), and puromycin-sensitive aminopeptidase15 amino acids long. Beyond 15 amino acids, peptides
(PSA) (Johnson and Hersh, 1990; Stoltze et al., 2000).are exclusively trimmed by the peptidase TPPII, which
Overexpression of LAP (Reits et al., 2003) or TOP (Yorkdisplays both exo- and endopeptidase activity. Sur-
et al., 2003) reduces class I expression, suggesting aprisingly, most proteasomal degradation products are
role for these peptidases in trimming peptides for MHChandled by TPPII before presentation by MHC class I
class I molecules. In addition, the ER-associated amino-molecules. We define three distinct proteolytic activi-
peptidase is also involved in peptide generation for MHCties during antigen processing in vivo. Proteasome-
class I molecules but also their destruction (Serwold etgenerated peptides relevant for antigen presentation
al., 2002; York et al., 2002). Since cells lack cytoplasmicare mostly 15 amino acids or longer. These require
carboxypeptidase activities (Reits et al., 2003), the pro-TPPII activity for further trimming before becoming
teasome should generate the correct C terminus of pep-substrates for other peptidases and MHC class I. The
tides for the MHC class I peptide binding groove (Cascioheterogeneous pool of aminopeptidases will process
et al., 2001), unless endopeptidases exist. TPPII appearsTPPII products into MHC class I peptides and beyond.
to be essential for the generation of a particular HIV
epitope (Seifert et al., 2003) and exhibits endopeptidaseIntroduction
activity in vitro (Geier et al., 1999; Seifert et al., 2003).
These data suggest that various peptidases modify the
The proteasome is the dominant cellular protease de-
pool of class I peptides. Although there may be special-
grading intracellular proteins (Kloetzel, 2001; Rock et ization in location, substrate specificity, and amounts,
al., 1994), including many newly synthesized proteins their collective activity may determine the outcome of
(Reits et al., 2000; Schubert et al., 2000). Only a small a MHC class I response, since more than 99% of the
fraction of these peptides is translocated by the trans- peptides are destroyed by peptidases (Princiotta et al.,
porter associated with antigen processing (TAP) into the 2003; Reits et al., 2003). The few peptides escaping
lumen of the endoplasmic reticulum (ER), where they peptidase activity may represent a small pool of particu-
can bind newly synthesized MHC class I molecules (re- lar peptides that resist proteases due to amino acid
viewed by Yewdell et al., 2003). The vast majority of sequence and peptide length. Alternatively, a nonselec-
generated peptides are however degraded by cyto- tive process that degrades peptides at random may
plasmic peptidases before being able to interact with be operational with some inefficiency in the form of
TAP (Fruci et al., 2003; Reits et al., 2003). In addition, escaping peptides. This is, however, hard to determine
peptides can be trimmed by the ER-associated amino- on the basis of the few known in vitro-determined pepti-
peptidase ERAAP or ERAP1 before binding to MHC dase specificities.
class I molecules (Saric et al., 2002; Serwold et al., 2002; Here, we have studied the specificity of the collective
York et al., 2002), while other peptides are translocated cytoplasmic peptidase activities using internally quenched
back into the cytoplasm by the Sec61 complex and peptides introduced into living cells. Peptides are rapidly
degraded by aminopeptidases without dramatic se-
quence specificity. N-terminal but not C-terminal exten-*Correspondence: j.neefjes@nki.nl
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Figure 1. Detecting Peptidase Activity in Liv-
ing Cells
(A) Principle of detecting peptidase activity.
Internally quenched peptides are injected in
cells. The emission of the fluorescein side
chain (F) is absorbed by the quencher Dabcyl
moiety (Q). Emission of fluorescein can only
be detected when the two groups are spa-
tially separated after degradation.
(B) Representative degradation curves of two
peptides in vivo. Model peptide T[K-Dabcyl]-
NKTER[C-Fluorescein]Y (black line) was mi-
croinjected (indicated by the arrow) in a single
melanoma cell (Mel JuSo), and the appear-
ance of fluorescence was monitored at 520
nm. This experiment was repeated with the
same peptide with an N-terminal D amino
acid (D-T)[K-Dabcyl]NKTER[C-Fluorescein]Y
(gray line). The figure shows a merge of the
two experiments. Fluorescence appears im-
mediately after introduction in the cell and
goes to completion.
sion increases the half-life of the reporter peptide, which the 9-mer peptide was no substrate for proteasomes
(data not shown). This agrees with the observation thatis in line with observations that carboxy peptidase activ-
ity is absent in the cytoplasm. Beyond 15 amino acids, N-terminally protected peptides were stable in vivo. Ap-
parently, small peptides are digested in the cytoplasmpeptides become the exclusive substrate for TPPII that
removes N-terminal sequences, including nine potential exclusively by aminopeptidases and not by carboxy or
endopeptidases (Reits et al., 2003).amino acid epitopes. However, epitopes located at the
C terminus of these larger peptides are presented less
efficiently suggesting that TPPII can generate but also Sequence Specificity of the Intracellular
Peptidase Pooldestroy epitopes. We show that TPPII plays an important
role in antigen processing, as most proteasomal prod- Some aminopeptidases like LAP have defined substrate
specificities (Turzynski and Mentlein, 1990). Variation inucts require further processing by TPPII for MHC class
I presentation. As a consequence, peptide generation the amino acid sequence of the reporter peptide may
therefore affect the degradation rate in vivo. This is im-for MHC class I is severely hampered when TPPII activity
is inhibited. portant since an increased peptide half-life should theo-
retically correlate with a better chance to reach the ER
lumen, resulting in an improved class I presentation. ToResults
examine whether the cytoplasmic peptidases collec-
tively show sequence selectivity, we systematically var-Aminopeptidases Degrade Peptides In Vivo
An internally quenched 9-mer peptide was used to de- ied amino acids positioned at the first, second, third,
or last position within an internally quenched reportertect peptidase activity in vivo. The quenched reporter
peptide (T[K-Dabcyl]NKTER[C-Fluorescein]Y) contains peptide sequence (Figures 2A–2D). The variable amino
acids (indicated as “X”) were representatives of everya quenching Dabcyl group and a fluorescein group cou-
pled to amino acid two and eight, respectively. The chemical group of amino acids. With the exception of
the third amino acid position, the variable amino acidsquencher efficiently absorbs emission of the nearby flu-
orescein group, and fluorescence will only be detected were positioned outside the quencher-fluorophore box
(indicated by “K” and “C”). Peptide degradation alwayswhen amino acids two and eight are separated in space
as the result of peptidase activity (Figure 1A). As shown started immediately after its introduction in living cells
by microinjection and went to completion. Surprisingly,before (Reits et al., 2003), fluorescence appeared almost
immediately after microinjection of the quenched re- the different amino acids hardly affected the peptide
half-life (Figures 2A–2D, the t1/2 of full peptide degrada-porter peptide into living Mel JuSo cells, and degrada-
tion went to completion with a half-life of a few seconds tion is plotted), indicating that the collective pool of
peptidases is able to efficiently degrade every peptide(t1/2  4.1 0.9 s; Figure 1B). The peptide was degraded
exclusively by aminopeptidases, as blocking the free N sequence almost irrespective of the type of amino acid
at these positions. The differences in peptide half-lifeterminus of the peptide by a protective group inhibited
degradation (Reits et al., 2003). Treatment of cells with of the tested combinations are within a factor 2. The
rate of degradation decreased only when the N-terminallactacystin to inhibit proteasomal degradation had no
effect on the rapid rate of degradation, indicating that amino acid was replaced by an unnatural D amino acid
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amino acid is not cleavable. In summary, the heteroge-
neous pool of cytoplasmic peptidases in cells efficiently
digests peptides with no major sequence selectivity un-
less stereoisomeric D amino acids are introduced.
Cytoplasmic Peptidase Activity, Substrate Length,
and Antigen Presentation by MHC Class I
Since the second amino acid of the original reporter
peptide contained the quencher group, we repositioned
the quencher molecule to the third position and ex-
tended the N terminus by one additional amino acid to
examine the effect of amino acid variations at the second
position. While again no major effect of the sequence
variation was observed, the half-life of the reporter pep-
tide increased (Figure 2D). Apparently the presence of
two additional N-terminal amino acids reduced proteo-
lytic access to the quencher-fluorophore reporter. To
examine the relationship between peptide length and in
vivo half-life, the reporter peptide was extended either
at the C or N terminus with a repeat of amino acids
again representing the various chemical groups (Figure
3). When the C terminus was extended with three, six,
or twelve amino acids, no increase in the half-life of the
reporter sequence was observed (Figure 3A). Even a
further extension by 18 amino acids did not increase
the short half-life of the N-terminal reporter sequence
in vivo. Apparently, trimming aminopeptidases are de-
grading the first N-terminal amino acids of the reporter
sequence at similar rates, irrespective of the length of
the C terminus.
If correct, then addition of amino acids at the N termi-
nus should increase the reporter’s half-life, as trimming
aminopeptidases have to remove more amino acids be-
fore encountering the internally quenched reporter. In-
deed, extending the N terminus up to three additional
amino acids increased the half-life of the reporter se-
quence (Figure 3B). Surprisingly, further extension by 6,
11, or 18 additional amino acids did not lead to a further
increase in half-life. To exclude that the presence of one
or more proline residues in the N-terminal extension
would influence aminopeptidase activity (Yellen-Shaw
et al., 1997), we replaced these residues for threonine
residues. The half-life of these model peptides was not
affected by the proline to threonine exchange (data not
shown). Despite more N-terminal amino acids, the half-
life of the reporter sequence remains similar when pre-Figure 2. Sequence Specificity of the Collective Peptidase Activities
in Living Cells ceded by more than five amino acids, which might sug-
(A–D) 9-mer model peptides with systematic amino acid variations gest that another cytoplasmic peptidase is involved in
at position 1 (A), 3 (B), and 9 (C) were tested for in vivo degradation peptide degradation for substrates over 15 amino
by Mel JuSo cells. The sequences are shown in every panel with K acids in length.
representing Lys-Dabcyl, C the Cys-fluorescein, and the enlarged
Although reporter peptides that are N-terminally ex-and underlined amino acid X the variable amino acid. A 10-mer
tended have an increased in vivo half-life, this does notpeptide was used to test the effect of variable amino acids at posi-
necessarily mean that N extended antigens are bettertion 2 (Figure 2D). Kat position 2 was preceeded by F. The variations
(introduced at position X) represent the different chemical groups presented by MHC class I. To test whether extensions
of amino acids with, in addition, P as imino acid and G as the affected antigen presentation by MHC class I molecules,
smallest amino acid. L represents the hydrophobic; D, acidic; K, a HLA-A2-restricted influenza M epitope was expressed
basic; F, aromatic; and T, neutral amino acids. D-[T] is the D amino
with N- or C-terminal extensions (Table 1) correspondingacid T. Shown is the half-life in seconds for every peptide (SEM).
to the sequences used in the model peptides tested in
Figures 3A and 3B. The various minigenes were cloned
in a vector upstream of an IRES sequence followedisomer (Figures 1B and 2A). This suggests that a large
portion of the collective peptidase activities cleaves be- by GFP to ensure cotranscriptional expression. These
constructs were stably expressed in HLA-A2-expressingtween the first and second amino acid, as the peptide
bond between the N-terminal D and the following L Mel JuSo cells and sorted for equal GFP expression
Immunity
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Figure 3. Substrate Length Specificity of the
Collective Peptidase Activities
(A) C-terminal extensions. The 9-mer reporter
peptide sequence T[K-Dabcyl]NKTER[C-Flu-
orescein]Y containing the quencher-fluoro-
phore combination was C-terminally ex-
tended with 3, 6, 11, or 18 amino acids. The
extension is a repeat of the different amino
acids as tested in Figure 2. The peptides were
introduced in living cells, and the half-life was
determined. Half-life (SEM) is depicted.
(B) N-terminal extensions. The reporter pep-
tide Y[C-Fluorescein]RETKN[K-Dabcyl]T has
the reverse sequence as the reporter used
for the C-terminal extensions. Also, the se-
quence of the N-terminal extensions is mir-
rored. The reporter peptide was extended
with 1, 3, 6, 11, or 18 amino acids, and the
half-life was determined in cells (SEM).
(C) The effect of N- or C-terminal extensions
on HLA-A2-restricted antigen presentation of
the influenza NP-epitope. Cells expressing
both HLA-A2 and the influenza M-epitope,
the epitope with one or three C-terminal
amino acid extensions (C 1 or C 3), or the
epitope with N-terminal extensions varying
from 1 to 15 additional amino acids (N  1 to
N  15) (see Table 1). Equal expression of
the minigen was controlled through GFP ex-
pression from the same transcript. Activation
of the influenza M epitope-specific, HLA-A2-
restricted T cell clone was measured by IFN
secretion after o/n culture at different ef-
fector/target cell ratios. The experiments
were performed in triplicate, and means
(SEM) are indicated.
before determining the T cell response. The influenza Moreover, extending the N terminus with 15 amino acids
epitope with a C-terminal extension of one or three resulted in a reduced presentation of the influenza epi-
amino acids were not presented. Mel JuSo cells are tope (Figure 3C). Since the sequence of the shorter ex-
apparently unable to generate the properly sized 9-mer tensions is repeated in the longest sequence, these data
influenza epitope in the absence of carboxypeptidase indicate that N-terminal extensions do not necessarily
activity (Reits et al., 2003). Contrary to what may be improve antigen presentation. The longest extension
expected, extending the N terminus of the influenza generates a minigene product of 28 amino acids and
epitope with one or five amino acids did not increase may be a substrate for the previously observed pepti-
presentation of influenza M epitope to specific T cells. dase activity that is active on larger fragments and may
generate, though less efficiently, this specific epitope.
To investigate the role of this peptidase in more detail,
Table 1. Peptide Epitopes Expressed by Minigenes for CTL Assay peptides of 27 amino acids with the reporter sequence
Epitope (M) GLIGFVFTL at various positions were microinjected (Figure 4A). The
fluorophore-quencher box at the C terminus of a 27-Epitope (C  1) (M) GLIGFVFTL P
mer peptide was degraded relatively slowly as expectedEpitope (C  3) (M) GLIGFVFTL PGL
Epitope (N  1) (M) D GLIGFVFTL for N-terminal-extended peptides. When the reporter
Epitope (N  3) (M) FKD GLIGFVFTL was placed at the N terminus, fluorescence appeared
Epitope (N  5) (M) GPFKD GLIGFVFTL almost immediately due to rapid separation of the
Epitope (N  15) (M) FKDLGPFKDLGPFKD GLIGFVFTL
quencher and the fluorescein group. However, when
Proteasome, TPPII, and Antigen Presentation
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Figure 4. Characterizing Peptidase Activity
for Longer Peptides
(A) Positional variations. The half-life of the
27-mer peptide shown in Figures 3A and 3B
was compared with a 27-mer containing the
reporter sequence in the middle. The half-
life of the peptides was determined in living
cells (SEM).
(B) The effect of N-terminal modifications on
degradation of the 27-mer peptide. Amino
acids one or one and two were exchanged
for D amino acids (shown in bold and under-
lined) in the 27-mer model peptide with the
reporter in the middle (as in Figure 3D). Alter-
natively, the free N terminus of this peptide
was blocked with naftylenesulfone (indicated
by an asterisk). The peptides were introduced
in living Mel JuSo cells and degradation mea-
sured. The half-life (SEM) is depicted. No
degradation of the N-terminally blocked pep-
tide was observed within a period of 200 s.
the same fluorescent-quencher reporter sequence was tabindide is a water-soluble and highly specific revers-
ible and competitive inhibitor for TPPII (Breslin et al.,placed in the center of the 27-mer peptide, degradation
was as fast as when the reporter sequence was placed 2002; Ganellin et al., 2000; Renn et al., 1998; Rose et
al., 1996) and is a small indole-based structure withat the N terminus (Figure 4A). This is unlikely due to
gradual N-terminal trimming, since peptides with only some inherent instability in solution (Breslin et al., 2002).
We tested the effect of butabindide on the degradationthree to six amino acids N-terminally of the reporter
sequence are degraded considerably slower than this of a 20-mer internally quenched peptide microinjected
into cells (Figure 5A). The addition of 104M butabindidepeptide (Figure 3B). Surprisingly, a corresponding 18-
mer peptide with the reporter sequence at the C termi- to the medium was sufficient to completely inhibit the
degradation of the 20-mer peptide in living cells. Sincenus was degraded almost as fast as the 27-mer with
the centered reporter sequence, suggesting that they cells were always microinjected under serum-free con-
ditions, the effect of serum on the stability of butabindideare not substrates for trimming amino peptidases but
that the 18- and 27-mer are possibly targeted by an was tested. Even small amounts of fetal calf serum pre-
vented the inhibitory effect of butabindide (Figure 5A).endopeptidase that cleaves these peptides into large
pieces, thereby separating the quencher and fluoro- To our knowledge, butabindide has not been success-
fully used in in vivo experiments before to inhibit peptidephore. To examine the requirements for an unmodified
N terminus, the 27-mer peptide with the reporter se- degradation by TPPII, which may be explained by the
apparent inhibitory effect of serum on butabindide treat-quence in the middle was modified by either placing one
or two D amino acids at the N terminus or by blocking the ment. To test the stability of butabindide in our experi-
mental system, the 20-mer internally quenched peptideN terminus (Figure 4B). Replacing the first two amino
acids by D amino acids did not influence the half-life of was microinjected in cells (in serum-free medium) at
various times after addition of the inhibitor at 104M.the reporter sequence. However, blocking the free N
terminus prevented degradation of the 27-mer peptide Complete inhibition of peptide degradation was ob-
served until 1.5 hr after butabindide addition, afterin vivo. These data suggest that long peptides are han-
dled by distinct peptidases that can remove larger which peptide degradation was recovering (data not
shown).pieces but require a free N terminus.
We subsequently measured the degradation rates of
peptides, varying in size between 9 and 27 amino acids,Long Peptides Are Selectively Degraded by TPPII
Since proteasomal activity may be involved in degrading by microinjecting these in cells cultured in the presence
or absence of butabindide. The rate of degradation forlarge peptide fragments, we measured peptide degrada-
tion in the presence of proteasome inhibitor, but no peptides up to 15 amino acids was not significantly
affected by inhibition of TPPII, although the N-terminallychange in peptide half-life was observed (data not
shown). Another candidate might be the large peptidase extended 15-mer peptide was degraded less efficiently
under these conditions. Presentation of the 14-mer influ-complex TPPII, which has reported exo- and endopepti-
dase activities (Geier et al., 1999). To test whether TPPII enza epitope expressed from minigenes was not af-
fected when cells were first stripped to dissociate mostwas the peptidase specialized in the degradation of the
long peptides, the inhibitor butabindide was used. Bu- surface class I molecules by acid wash and cultured for
Immunity
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Figure 5. TPPII and the Generation of Peptides by TPPII in Living Cells
(A) The effect of serum on the stability of the TPPII inhibitor butabindide. Cells were cultured in the presence or absence of FCS while incubated
with 100 M butabindide. Subsequently, the 20-mer peptide T[K-Dabcyl]NKTERR[C-Fluorescein]YPGLDKFPGLDK was microinjected and
degradation was measured.
(B) The effect of butabindide on the presentation of an expressed 14-mer peptide. HLA-A2-expressing Mel JuSo cells were transfected with
a 14-mer peptide (N  5; see Figure 3C). Cells were acid stripped followed by culture for 16 hr in the presence or absence of butabindide
(refreshed every 60 min). Activation of the influenza M epitope-specific, HLA-A2-restricted T cell clone was measured by IFN secretion after
o/n culture at E/T ratio 1:1. The experiments were performed in 6-fold, and means (SEM, corrected for background) are indicated.
(C) The effect of inhibition of TPPII on peptide degradation in living Mel JuSo cells. Peptides of different length with the reporter sequence
at different positions (as indicated, for sequence see Figure 3) were microinjected in cells cultured under serum-free conditions and in the
absence or presence of 100 M butabindide. Degradation of the peptides was determined by fluorescence emission at 540 nm and the half-
life of the peptides (SEM) is depicted. D.N.O., degradation not observed within the time of analysis (200 s).
16 hr in the absence or presence of butabindide followed dependent on TPPII activity (Figure 5C) irrespective of
the position of the reporter sequence, since no degrada-by the CTL assay (Figure 5B). This indicates that buta-
bindide treatment did not inhibit synthesis, assembly, tion was observed (D.N.O.) in the presence of butabin-
dide. Apparently, peptides longer than 15 amino acidsand transport of MHC class I molecules, nor presenta-
tion of small peptides. However, the degradation of pep- can only be efficiently degraded by TPPII in vivo.
To test whether butabindide affected proteasometides larger than 15 amino acids appeared to be critically
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Figure 6. Specificity of TPPII Inhibition
(A) The effect of butabindide on proteasome
activity. Cells were incubated for 2 hr with
either proteasome inhibitor or butabindide,
and accumulation of cyclin D1 was deter-
mined by Western blotting. DR chain was
probed as loading control.
(B) TPPII-specific siRNA inhibit degradation
of peptides longer than 15 amino acids. Mel
JuSo cells were transfected for 72 hr with
TPPII-specific siRNA from pSUPER coex-
pressing GFP. Control and GFP-expressing
cells were microinjected with various reporter
peptides in the presence of competing pep-
tides. The upper panel shows representative
degradation curves in control cells; the lower
panel shows representative degradation curves
in cells expressing TPPII siRNA. The 16-mer
peptide has a C-terminal reporter, resulting
in a slow degradation when compared to all
other peptides with N-terminal reporters.
degradation under these conditions, we cultured Mel This was determined after titration of “cold” 27-mer pep-
tides (containing a quencher but no fluorophore) withJuSo cells in the absence or presence of the proteasome
inhibitor MG132 or butabindide for 2 hr in serum-free constant amounts of quenched peptides to saturate
TPPII activity. At three times molar excess of cold 27-medium. Accumulation of the proteasome substrate
cyclin D1 was detected only after inhibiting the protea- mer peptide, an 8-fold reduction in rate of degradation
of the quenched 27-mer peptide was observed. Thissome (Agami and Bernards, 2000) and not when cells
were cultured in the presence of butabindide (Figure concentration of competing cold peptides was coin-
jected with the internally quenched peptides in control6A). To confirm that the effects of butabindide were due
to inhibition of TPPII, the peptide degradation experi- and siRNA expressing cells. The 9-mer reporter peptide
was rapidly degraded independent of TPPII saturationments were repeated after transient downregulation of
TPPII using a vector containing GFP and a siRNA con- or additional inhibition by siRNA (Figure 6B). Due to
competition with the cold 27-mer, the 16-mer, 20-mer,struct directed against TPPII (Seifert et al., 2003). Two
days after transfection, cells showed a downregulation and 25-mer reporter peptides were slower degraded
when compared to Figure 5C, but hardly any degrada-of TPPII expression up to sixty percent (data not shown).
Since TPPII is not fully downregulated, we measured tion was observed when microinjected cells expressed
siRNA. Although slower, the 15-mer reporter peptidepeptide degradation under saturated conditions in vivo.
Immunity
502
could apparently still be degraded by other peptidases peptides generated by the proteasome are lost before
encountering the peptide transporter TAP (Fruci et al.,in siRNA-expressing cells (Figure 6B). Similar to the re-
2003; Princiotta et al., 2003; Reits et al., 2003). Thesesults obtained with butabindide treatment, specific
peptides are degraded within seconds by cytoplasmicdownregulation of TPPII results in the inhibition of deg-
peptidases and most fail to associate with TAP withinradation of peptides longer than 15 amino acids.
this time window (Reits et al., 2003). A number of cyto-
plasmic peptidases have been characterized that mayTPPII and the Generation of MHC Class I Peptides
contribute to peptide processing for MHC class I presen-TPPII may be specialized in degrading large peptide
tation. For example, LAP is a peptidase that is upregu-fragments but at the same time it may also destroy and
lated by IFN and able to degrade peptides destinedcreate antigenic peptides. To examine the importance
for antigen presentation (Beninga et al., 1998; Reits etof TPPII in the proteolytic pathway resulting in class I
al., 2003). TOP is another peptidase known to affect thepeptides, we first assayed the cleavage pattern of TPPII.
class I peptide pool (Saric et al., 2001) and MHC classTherefore, a series of 16-mer peptides was generated
I molecules are upregulated when TOP is inactivated bywith the reporter sequence at the C terminus and with
siRNA (York et al., 2003). TPPII is reported to be involvedan increasing number of D amino acids at the N terminus
in the generation of a HIV epitope (Seifert et al., 2003)(Figure 7A). Degradation of these peptides was inhibited
and may generate C termini of epitopes that are notby butabindide, implying that the peptides were handled
made by the proteasome. It has been suggested thatby TPPII (data not shown). Proteases can only cleave
TPPII can compensate for some activities of the protea-the peptide bond between natural L amino acids and
some (Glas et al., 1998) but how, if at all (Princiotta etnot between D and L or between D amino acids. Replac-
al., 2001), is unclear. The specificity of the cytoplasmicing the first one or two N-terminal amino acids reduced
peptidases may be an important determinant in the out-the rate of degradation of the reporter segment, proba-
come of MHC class I antigen presentation if particularbly by affecting the exopeptidase activity of TPPII that
peptide sequences would be more resistant. Althoughcan remove one to three amino acid parts from the N
the substrate specificity of some peptidases is known,terminus (Tomkinson, 1999). However, no further de-
it is unknown whether the combined in vivo activities andcrease in the rate of degradation was observed when
enzyme concentration destroys different cytoplasmicmore L amino acids were replaced by D amino acids.
peptides equally.Apparently, TPPII has two activities: one activity that
Here, we show that variation of amino acids at theremoves small fragments from the N terminus and a
first, second, third, or last position does not result insecond but slower activity that generates larger frag-
major differences in the half-life of introduced peptides.ments. Since a fragment containing eight D amino acids
Although the quencher and/or fluorophore might affecthas to be cleaved after the following L amino acid, TPPII
the ability of some peptidases to hydrolyse the reporteris apparently able to generate 9-mer fragments (or
peptide, our data suggests that the heterogeneous poollonger).
of cytoplasmic peptidases destroys small peptides rap-To determine the relevance of TPPII in peptide genera-
idly but fairly irrespective of amino acid sequence. Sincetion for MHC class I molecules, both Mel JuSo cells and
peptides are degraded exclusively by aminopeptidasesfreshly isolated peripheral blood lymphocytes (PBLs)
(Reits et al., 2003), additional N-terminal amino acidswere stripped to dissociate most surface class I mole-
should increase the half-life of an antigen, as has beencules by acid wash. The cells were subsequently cul-
suggested previously (Cascio et al., 2001). The half-lifetured in the presence or absence of the proteasome
of the 9-mer reporter sequence increases from 4 to 30 s
inhibitor lactacystin, butabindide, or a combination of
when three additional amino acids are present at the N
the two inhibitors, all under serum-free conditions. Bu-
terminus. Apparently, every additional amino acid in-
tabindide was readded every hour. After 4 hr, MHC class creases the reporter’s half-life with around 6 s until the
I molecules at the cell surface were labeled with the peptide becomes longer than 15 amino acids. Still, when
antibody W6/32, followed by FACS analysis (Figure 7B). minigene constructs with N-terminal extensions are ex-
Surprisingly, butabindide treatment resulted in a similar pressed, no increased level of influenza M-epitope pre-
reduction in cell surface MHC class I as treatment with sentation is observed. In fact, a long N-terminal exten-
proteasome inhibitor, while the combination of the two sion (15 additional amino acids) results in decreased
inhibitors only had a marginal additive effect. Identical levels of antigen presentation. This may be surprising,
effects were obtained with the less specific TPPII inhibi- since the short N-terminal sequences were included in
tor AAF-CMK (data not shown). Given the substrate the long N-terminal sequence, but it suggests that the
specificity of TPPII, our data suggests that a major por- antigenic sequence within the long peptide is partially
tion of proteasomal products consists of long peptides degraded by an endopeptidase. Extending the total
(over 15 amino acids) that are subsequently targeted by length of the reporter peptide beyond 15 amino acids
TPPII. Since these peptides will be too long for MHC does not reduce the rate of degradation any further,
class I loading, TPPII will act as a crucial intermediate which suggests that these peptides were handled differ-
between proteasomes, cytoplasmic or ER peptidases, ently from shorter peptides by the cytoplasmic amino-
and MHC class I molecules. peptidases. Extending the C terminus of the NP-epitope
prevents presentation by MHC class I, which confirms
Discussion the observed absence of cytoplasmic carboxypeptidase
activities (Reits et al., 2003).
The efficiency of antigen presentation by MHC class I The enzyme involved in long peptide degradation
should display aminopeptidase activity, since blockingmolecules is amazingly low, since more than 99% of the
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Figure 7. Major Role for TPPII in Antigen Presentation
(A) TPPII and the generation of 9-mer peptides. A 16-mer peptide was synthesized with the reporter sequence Y[C-Fluorescein]RETKN
[K-Dabcyl]T at the C terminus. Either one, two, five, or eight N-terminal amino acids were exchanged for their corresponding D stereoisomers that
cannot be handled by natural proteases. The peptides were introduced in living cells, and degradation of the reporter sequence was measured.
(B) TPPII and the generation of peptides for MHC class I molecules. Mel JuSo cells (left) and human PBLs (right) were acid stripped followed
by culture in the presence or absence of lactacystin, butabindide, or a combination of the two inhibitors. Butabindide was refreshed every
60 min. After 4 hr, the surface expression of MHC class I molecules was determined by FACS analysis. The inhibitors used are indicated in
the figure.
(C) Model of the first proteolytic steps in MHC class I antigen presentation. The proteasome releases mainly products of 16 amino acids or
longer. These long peptides are handled almost exclusively by TPPII. TPPII can destroy but also generate antigenic peptides for TAP by either
removing small packages of amino acids or making large fragments, thereby creating the C terminus. Smaller peptides can be produced
directly by the proteasome and after further trimming by TPPII. Other peptidases (represented as X, Y, and Z) that include TOP and LAP target
these substrates. Antigenic peptides translocated by TAP can be generated exclusively by the proteasome, by the proteasome and TPPII,
and by the proteasome, often TPPII, and other peptidases. TPPII appears to be an important intermediate between the proteasome and the
rest of the peptidase pool involved in trimming fragments to antigenic peptides and mainly free amino acids.
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the N terminus also protects the long peptides. Thimet MHC class I molecules after an acidic wash in the pres-
oligopeptidase has been shown in vitro to select peptide ence of proteasome inhibitors or butabindide. Surface
substrates between 8 and 16 amino acids in length (Saric expression of MHC class I was equally affected by both
et al., 2001), but it is unclear whether it can degrade inhibitors, and hardly any additive effect of the combina-
longer peptides as well. TPPII is a protease that is even tion of the two inhibitors was observed. Peptide supply
larger than the proteasome (5–9 MDa) and is able to for MHC class I molecules but not peptide presentation
generate antigenic fragments by endopeptidase activity is affected by butabindide treatment, suggesting that
(Geier et al., 1999). Although TPPII can degrade small TPPII is critical for MHC class I peptide generation. In
trimer substrates in vitro (Geier et al., 1999), it is unclear vitro data suggest that the proteasome generate an
whether this reflects the activities of the complex in vivo. array of peptides between three and twenty-two amino
Regulating subunits may not be copurified with the TPPII acids with two-thirds too short to function in antigen
core, similar to the situation with the proteasome where processing (Kisselev et al., 1999). However, it is likely
usually the 20S core is purified without the 19S subunits. that peptides reenter the proteasome multiple times dur-
TPPII is upregulated when various activities of the pro- ing in vitro digestion, possibly resulting in shorter prod-
teasome are inhibited (Geier et al., 1999; Princiotta et ucts than generated in vivo. Peptides are no substrate
al., 2001), which can be envisaged when under these for the proteasome in living cells (Reits et al., 2003), and
conditions the proteasome is generating larger break- reentry into the proteasome will not be a relevant route in
down intermediates requiring further fragmentation by vivo. Our data imply that a major portion of proteasomal
TPPII. Alternatively, TPPII could replace the proteasome products is larger than 15 amino acids and require fur-
but should then be able to unfold and deubiquitinate ther degradation by TPPII before becoming relevant for
substrates. Whether this is possible is unknown. TPPII MHC class I. It has been suggested that the proteasome
is at least unable to degrade the proteasomal substrate usually generates the proper C terminus of class I bind-
cyclin D1. When we repeated the peptide degradation ing peptides (Cascio et al., 2001) with aminopeptidases
experiments in the presence of the specific TPPII inhibi- only trimming from the N-terminal side. Our data pro-
tor butabindide or after downregulation of TPPII by pose a role for TPPII in this process since TPPII can
siRNA, we observed that TPPII was selectively involved generate at least 9-mer (antigenic) fragments containing
in the degradation of peptides of over 15 amino acids, a new C terminus. TPPII may thus generate but also
whereas the degradation of smaller peptides was not destroy antigenic peptides, which may explain why a
affected. Substrates with the reporter located nine long minigene-expressed peptide is less efficiently pre-
amino acids from the N terminus were very efficiently sented than minigene-expressed peptides shorter than
degraded, suggesting that TPPII cleaves somewhere 15 amino acids.
between the ninth and eleventh residue. Experiments By visualizing peptidase activity in living cells, we have
with D amino acid-containing substrates suggest that defined TPPII as a critical player in antigen processing
TPPII can remove blocks of one to three amino acids and presentation by MHC class I molecules. Our data
for the N terminus but also fragments of nine amino suggests the following sequence of events to occur for a
acids or more (albeit less efficient). This corresponds successful class I response (Figure 7C). The proteasome
to the reported in vitro activities of TPPII, where TPPII digests proteins mainly in fragments larger than 15
requires a free N terminus and preferably removes frag- amino acids. TPPII trims these peptides into smaller
ments of two to three amino acids (Tomkinson, 1999). fragments that may include proper class I binding pep-
It is unclear whether there is a maximal size for the tides. A variety of peptidases (including TOP, LAP, and
peptide substrates for TPPII, but it may cleave at various ERAAP) then continues the digestion into even smaller
positions within a substrate, since a reporter sequence products. These three proteolytic steps act in a process
in the middle of a 27-mer peptide is degraded as rapidly degrading proteins down to small fragments and amino
as an N-terminally positioned reporter. The observed
acids, occasionally generating a class I binding peptides
differences in half-life of C-terminally positioned report-
instead of destroying it. In every step, peptides may
ers in peptides longer than 16 amino acids may be the
escape further trimming by cytoplasmic peptidase activ-result of cleavage by TPPII, resulting in differently sized
ity by being transported into the ER by TAP for consider-fragments containing the reporter sequence that need
ation by ERAAP and MHC class I. Most peptides willsubsequent degradation by aminopeptidases. How
however be degraded into single amino acids.TPPII decides to remove small or long fragments is un-
clear. One possibility is that additional complexes regu-
Experimental Procedureslate the activities, but whether TPPII has regulatory part-
ners determining recognition and degradation and Synthetic Peptides
selecting long peptides is unclear. Still, TPPII may play The various fluorescent peptides were synthesized by solid-phase
an important role in the degradation process of proteins strategies using an automated multiple peptide synthesizer (Syro II,
MultiSyntech, Witten, Germany) using Fmoc chemistry. Fluoresceinback to amino acids. The proteasome is specialized
was covalently coupled to the cysteine residue using fluorescein-in the digestion of ubiquitinated proteins that require
5-iodoacetamide (Molecular Probes, Leiden, The Netherlands).unfolding (Glickman and Ciechanover, 2002), whereas
Fmoc-L-Lys(Dabcyl)-OH was obtained from Neosystems (France).TPPII targets large peptide substrates and possibly un-
All peptides were HPLC purified (95% pure) and validated by
folded proteins. TOP and other peptidases may then mass spectrometry.
degrade peptides that are too small for TPPII.
We tested the role of TPPII both in peptide generation Peptide Degradation Analysis
in vivo but also in peptide generation for MHC class I Cells on coverslips were placed on an inverted Zeiss Axiovert 135
microscope equipped with a dry Achroplan 63	 (NA 0.75) objective.molecules by following cell surface reappearance of
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Peptides were quantified by their red appearance (Dabcyl) using Cancer Society (NKB 2001-2416, NKB 2003-2861) and the Nether-
lands Organization for Scientific Research.photospectrometry and mixed with Fura Red (Molecular Probes,
Leiden, The Netherlands) as a microinjection marker. Excitation of
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